Given that agents targeting IL‐6 signaling have been used in global inflammation disorders,[53] targeting CD146 to stimulate IL‐6 signaling in ATMs presents a promising alternative strategy for obesity and other metabolic syndromes that might be used to influence IL‐6 signaling effects. Here, MCAM is linked to metabolic syndrome.